Vaxcyte had its Relative Strength (RS) Rating upgraded from 70 to 76 Tuesday — a welcome improvement, but still below the 80 or higher score you prefer to see.
This exclusive rating from Investor's Business Daily tracks share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if Vaxcyte can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Vaxcyte is now considered extended and out of buy range after clearing a 76.00 buy point in a second-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% EPS growth last quarter, while sales growth came in at 0%.
The company earns the No. 200 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
